An2 Therapeutics, INC Form 4 insider transactions

AN2 Therapeutics, Inc. Director Gilbert Lynn Marks was granted 19,111 stock options with an exercise price of $1.19, vesting on March 31, 2026.

AN2 Therapeutics, Inc. Director Kabeer Aziz was granted 19,111 stock options with an exercise price of $1.19 per share, vesting on March 31, 2026.

Director Joseph S. Zakrzewski acquired 10,523 shares of AN2 Therapeutics common stock in lieu of cash compensation on April 10, 2025.

Patricia A. Martin, a director of AN2 Therapeutics, reported the acquisition and disposal of common stock on April 10, 2025, according to a Form 4 filing.

AN2 Therapeutics Director Gilbert Lynn Marks acquired 9,705 shares of common stock as non-cash compensation, increasing his total beneficial ownership to 41,507 shares.

Director Kabeer Aziz reports acquisition and disposal of AN2 Therapeutics shares, including shares issued in lieu of cash compensation.

Sanjay Chanda, Chief Development Officer of AN2 Therapeutics, reports acquisition and disposal of common stock and stock options.

Lucy Day, CFO of AN2 Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) in the company.

Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.

CEO Eric Easom reports acquisition of stock and options in AN2 Therapeutics, including restricted stock units and stock options vesting over four years.

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.

AN2 Therapeutics' Chief Financial Officer, Lucy Day, sold 2,957 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

Sanjay Chanda, Chief Development Officer at AN2 Therapeutics, sold 2,957 shares to cover tax obligations related to vesting Restricted Stock Units.

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, sold 2,029 shares of common stock to cover tax obligations related to vesting Restricted Stock Units.

AN2 Therapeutics' Chief Operating and Legal Officer, Joshua M. Eizen, sold 9,663 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Patricia A. Martin, a director at AN2 Therapeutics, acquired 3,166 shares of common stock as compensation in lieu of cash.

Kabeer Aziz, a director at AN2 Therapeutics, received 8,972 shares of common stock as compensation.

Director Gilbert Lynn Marks acquired 8,972 shares of AN2 Therapeutics stock as part of non-employee director compensation.

AN2 Therapeutics director Joseph S. Zakrzewski acquired 9,816 shares of common stock in lieu of cash compensation.

Robin Shane Readnour, a director at AN2 Therapeutics, received 9,077 shares of common stock as compensation and disclosed indirect holdings through MGC Venture Partners.

AN2 Therapeutics director Robin Shane Readnour, through affiliated entities, acquired shares of common stock in multiple transactions between December 6th and December 10th, 2024.

Director Robin Shane Readnour of AN2 Therapeutics has increased their indirect holdings through multiple purchases of common stock on November 26th and 27th, 2024.

Joseph S. Zakrzewski, a director at AN2 Therapeutics, purchased 2,000 shares of common stock at $1.40 per share on November 27, 2024.

Director Robin Shane Readnour of AN2 Therapeutics has increased their indirect holdings through multiple purchases of common stock.

Director Joseph S. Zakrzewski of AN2 Therapeutics, Inc. has increased his holdings through recent open market purchases of common stock.

AN2 Therapeutics CEO, Eric Easom, purchased 50,000 shares of common stock at $0.9994 per share on November 18, 2024.

Stephen David Prior, Chief Strategy Officer of AN2 Therapeutics, reports the acquisition of restricted stock units and stock options.

Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, reported the grant of stock and option awards.

Director Braden Michael Leonard reports purchasing 1,500,000 shares of AN2 Therapeutics at $1.04 per share on August 14, 2024.

RA Capital Management and related entities sold shares of AN2 Therapeutics at an average price of $1.08.